13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001744967
Total reported value
$1.2B
$1.2B
40 檔
21.3%
As reported in its official Q2 2024 Form 13F filing, Samsara BioCapital, LLC's tracked investment portfolio stood at $1.2B with 40 total positions.
Samsara BioCapital, LLC executed strategic sector rebalancing during Q2 2024, establishing 3 new positions while fully exiting 2 holdings and trimming 3 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CRGX | Cargo Therapeutics Inc | Stock-Other | 15.17% | — | +7.13% | |
| 2 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 12.43% | -2.44% | — | |
| 3 | SRRK | Scholar Rock Holding CORP | Stock-Other | 11.84% | -1.79% | — | |
| 4 | NGNE | Neurogene Inc | Stock-Other | 9.66% | +1.08% | — | |
| 5 | ACLXGBX | Arcellx Inc | Stock-Other | 5.24% | -0.68% | EXIT | |
| 6 | CLYM | Climb Bio Inc | Stock-Other | 4.85% | — | — | |
| 7 | NKTX | Nkarta Inc | Stock-Other | 4.66% | +0.10% | — | |
| 8 | LENZ | Lenz Therapeutics Inc | Stock-Other | 4.37% | — | — | |
| 9 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 2.85% | — | — | |
| 10 | JSPR | Jasper Therapeutics Inc | Stock-Other | 2.49% | — | — | |
| 11 | ✓ | Hillevax Inc | Stock-Other | 2.42% | — | — | |
| 12 | ABVX | Abivax Sa-adr | Stock-Other | 2.35% | -0.01% | — | |
| 13 | ✓ | Acelyrin Inc | Stock-Other | 2.33% | — | — | |
| 14 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 2.17% | — | — | |
| 15 | SYRS | Syros Pharmaceuticals Inc | Stock-Other | 1.93% | — | — | |
| 16 | ZYME | Zymeworks Inc | Stock-Other | 1.78% | — | -31.45% | |
| 17 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 1.48% | — | — | |
| 18 | ✓ | Inozyme Pharma Inc | Stock-Other | 1.46% | — | — | |
| 19 | STRO | Sutro Biopharma, Inc. | Stock-Other | 1.35% | — | +31.11% | |
| 20 | GOSS | Gossamer Bio Inc | Stock-Other | 1.16% | -0.13% | — | |
| 21 | TNGX | Tango Therapeutics Inc | Stock-Other | 1.13% | — | — | |
| 22 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 1.05% | — | — | |
| 23 | CYPH | Cypherpunk Technologies Inc | Stock-Other | 1.00% | — | +264.91% | |
| 24 | IOBTQ | Io Biotech Inc | Stock-Other | 0.89% | — | — | |
| 25 | VTVT | Vtv Therapeutics Inc- Cl A | Stock-Other | 0.76% | -0.23% | — | |
| 26 | PRME | Prime Medicine Inc | Stock-Other | 0.58% | — | — | |
| 27 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 0.57% | — | — | |
| 28 | ✓ | Immatics NV | Stock-Other | 0.48% | — | -50.00% | |
| 29 | JANX | Janux Therapeutics Inc | Stock-Other | 0.39% | — | -75.00% | |
| 30 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 0.29% | — | — | |
| 31 | 1K0 | Igm Biosciences Inc | Stock-Other | 0.22% | — | — | |
| 32 | BOLT1EUR | Bolt Biotherapeutics Inc | Stock-Other | 0.16% | — | — | |
| 33 | LYRAGBP | Lyra Therapeutics Inc | Stock-Other | 0.16% | — | — | |
| 34 | ACRS | Aclaris Therapeutics Inc | Stock-Other | 0.16% | — | — | |
| 35 | RYI | Viracta Therapeutics Inc | Stock-Other | 0.08% | — | — | |
| 36 | ALLKGUSD | Allakos Inc | Stock-Other | 0.04% | — | — | |
| 37 | KRON1USD | Kronos Bio Inc | Stock-Other | 0.02% | — | — | |
| 38 | ✓ | Stock-Other | 0.01% | — | — | ||
| 39 | NUVB-WS | Nuvation Bio Inc -cw27 | Stock-Other | — | — | — | |
| 40 | SRZNW | Surrozen Inc-cw25 | Stock-Other | — | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CLYM | Climb Bio Inc | +4.9% | NEW | New buy |
| 2 | ✓ | Avadel Pharmaceuticals PLC ADR | +2.9% | NEW | New buy |
| 3 | MLYS | Mineralys Therapeutics Inc | +2.3% | — | Unchanged |
| 4 | CTNM | Contineum Therapeutics Inc-a | +2.2% | NEW | New buy |
| 5 | CRGX | Cargo Therapeutics Inc | +0.9% | +7.13% | Add |
| 6 | CYPH | Cypherpunk Technologies Inc | +0.7% | +264.91% | Add |
| 7 | ABVX | Abivax Sa-adr | +0.5% | — | Unchanged |
| 8 | SYRS | Syros Pharmaceuticals Inc | +0.5% | — | Unchanged |
| 9 | ACLXGBX | Arcellx Inc | +0.4% | — | Unchanged |
| 10 | ✓ | Hillevax Inc | +0.4% | — | Unchanged |
| 11 | TNGX | Tango Therapeutics Inc | +0.4% | — | Unchanged |
| 12 | RYTM | Rhythm Pharmaceuticals Inc | +0.3% | — | Unchanged |
| 13 | LENZ | Lenz Therapeutics Inc | +0.2% | — | Unchanged |
| 14 | VRNA | Verona Pharma PLC - Adr | +0.2% | — | Unchanged |
| 15 | JSPR | Jasper Therapeutics Inc | +0.1% | — | Unchanged |
| 16 | 430 | Terns Pharmaceuticals Inc | +0.1% | — | Unchanged |
| 17 | DAWNGBX | Day One Biopharmaceuticals I | +0.1% | — | Unchanged |
| 18 | GOSS | Gossamer Bio Inc | 0% | — | Unchanged |
| 19 | ACRS | Aclaris Therapeutics Inc | 0% | — | Unchanged |
| 20 | VTVT | Vtv Therapeutics Inc- Cl A | 0% | — | Unchanged |
| 21 | ALLKGUSD | Allakos Inc | 0% | — | Unchanged |
| 22 | KRON1USD | Kronos Bio Inc | — | — | Unchanged |
| 23 | ✓ | — | — | Unchanged | |
| 24 | SRZNW | Surrozen Inc-cw25 | — | — | Unchanged |
| 25 | PRME | Prime Medicine Inc | 0% | — | Unchanged |
| 26 | 1K0 | Igm Biosciences Inc | 0% | — | Unchanged |
| 27 | NUVB-WS | Nuvation Bio Inc -cw27 | 0% | — | Unchanged |
| 28 | RYI | Viracta Therapeutics Inc | 0% | — | Unchanged |
| 29 | BOLT1EUR | Bolt Biotherapeutics Inc | -0.1% | — | Unchanged |
| 30 | IOBTQ | Io Biotech Inc | -0.1% | — | Unchanged |
| 31 | STRO | Sutro Biopharma, Inc. | -0.1% | +31.11% | Add |
| 32 | ✓ | Immatics NV | -0.2% | -50.00% | Trim |
| 33 | ✓ | Acelyrin Inc | -0.3% | — | Unchanged |
| 34 | NGNE | Neurogene Inc | -0.3% | — | Unchanged |
| 35 | ✓ | Inozyme Pharma Inc | -0.4% | — | Unchanged |
| 36 | ZYME | Zymeworks Inc | -0.6% | -31.45% | Trim |
| 37 | AVU0 | Adverum Biotechnologies Inc | -0.6% | EXIT | Sold out |
| 38 | JANX | Janux Therapeutics Inc | -0.7% | -75.00% | Trim |
| 39 | NKTX | Nkarta Inc | -1.6% | — | Unchanged |
| 40 | LYRAGBP | Lyra Therapeutics Inc | -2.5% | — | Unchanged |
| 41 | ✓ | Avadel Pharmaceuticals PLC ADR | -2.5% | EXIT | Sold out |
| 42 | SRRK | Scholar Rock Holding CORP | -6.8% | — | Unchanged |
According to official SEC Form 13F filings, Samsara BioCapital, LLC reported a total U.S. public equity portfolio value of $1.2B across 40 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including CRGX, MLYS, SRRK) accounted for 21.3% of total reported equity market value during Q2 2024.
Top New Position Initiated
CLYM
市值: $23.2M
Top Position Liquidated / Trimmed
Avadel Pharmaceuticals PLC ADR
前期市值: $16.3M
During Q2 2024, Samsara BioCapital, LLC's top holdings by market value included CRGX (15.2%)、MLYS (12.4%)、SRRK (11.8%). The largest single position, CRGX, represented 15.2% of total portfolio value.
In Q2 2024, Samsara BioCapital, LLC made 11 total portfolio adjustments, initiating 3 new buys, adding to 3 positions, trimming 3 holdings, and fully liquidating 2 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.